HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Craven, D. E. Search for Related Content PubMed PubMed Citation Articles by Craven, D. E. Related Content Recent Advances in Chest Medicine

Preventing Ventilator-Associated Pneumonia in Adults^*

Sowing Seeds of Change

^* From Lahey Clinic Medical Center, Burlington, MA.

Correspondence to: Donald Craven, MD, Department of Infectious Diseases, Lahey Clinic Medical Center, Burlington, MA 01805; e-mail: donald.e.craven{at}lahey.org

Abstract

Ventilator-associated pneumonia (VAP), a major cause of ICU infection, results in high morbidity, mortality, and health-care costs. Multiple risk factors for VAP involve complex host factors and ubiquitous pathogens that require several different types of prevention strategies. Prevention efforts should focus on reducing bacterial colonization, and limiting aspiration, antibiotic exposure, and use of invasive devices. Although evidence-based prevention guidelines are available, they are lengthy, often ignored, and not implemented. New insights into the barriers to implementation of effective prevention programs are emerging. This article provides highlights from recent guidelines and publications discussing VAP prevention strategies and examines barriers to their implementation. Prevention and implementation of cost-effective strategies to reduce risk and improve patient outcomes should be prioritized. Clearly, prevention programs should be population specific and may vary among hospitals, but a multidisciplinary prevention team led by a "champion" is recommended to help set priorities, benchmarking goals, analyze data, and sow the seeds of change for risk reduction.

Key Words: antibiotics • evidence-based data • guidelines • infection control • Institute for Healthcare Improvement • intensive care • prevention of hospital-acquired pneumonia • ventilator-associated pneumonia

This article has been cited by other articles:

				M. H. Kollef, B. Afessa, A. Anzueto, C. Veremakis, K. M. Kerr, B. D. Margolis, D. E. Craven, P. R. Roberts, A. C. Arroliga, R. D. Hubmayr, et al. Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia: The NASCENT Randomized Trial JAMA, August 20, 2008; 300(7): 805 - 813. [Abstract] [Full Text] [PDF]

				M. Kollef SMART Approaches for Reducing Nosocomial Infections in the ICU Chest, August 1, 2008; 134(2): 447 - 456. [Abstract] [Full Text] [PDF]

				L. Vidaur, K. Planas, R. Sierra, G. Dimopoulos, A. Ramirez, T. Lisboa, and J. Rello Ventilator-Associated Pneumonia: Impact of Organisms on Clinical Resolution and Medical Resources Utilization Chest, March 1, 2008; 133(3): 625 - 632. [Abstract] [Full Text] [PDF]

				H. van Saene, J. van Saene, L. Silvestri, M. de la Cal, R. Sarginson, and D. Zandstra Iseganan Failure Due to the Wrong Pharmaceutical Technology Chest, October 1, 2007; 132(4): 1412 - 1412. [Full Text] [PDF]